Top

States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

After Capping Insulin Copays, Colorado Sets Its Sights on EpiPens

Almond, Soy Drinks Can Be Called Milk, FDA Proposes

GSK and Vir Biotech amend COVID-19 research partnership

Tag: Amneal Pharmaceuticals

FDA, Regulations

FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta

May 27, 2022

Via: Drugs.com

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta. The product will be marketed under the […]